Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
9(45%)
Results Posted
50%(1 trials)
Terminated
2(10%)

Phase Distribution

Ph phase_1
4
20%
Ph phase_2
6
30%
Ph not_applicable
8
40%
Ph phase_3
1
5%

Phase Distribution

4

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
4(21.1%)
Phase 2Efficacy & side effects
6(31.6%)
Phase 3Large-scale testing
1(5.3%)
N/ANon-phased studies
8(42.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

9

trials recruiting

Total Trials

20

all time

Status Distribution
Active(11)
Completed(2)
Terminated(2)
Other(5)

Detailed Status

Recruiting7
unknown5
Active, not recruiting2
Completed2
Not yet recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
20
Active
9
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (21.1%)
Phase 26 (31.6%)
Phase 31 (5.3%)
N/A8 (42.1%)

Trials by Status

active_not_recruiting210%
completed210%
not_yet_recruiting210%
unknown525%
recruiting735%
terminated210%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT03862911Not Applicable

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Active Not Recruiting
NCT05837767Not Applicable

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Recruiting
NCT05010031Phase 2

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Recruiting
NCT05717166Phase 3

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Recruiting
NCT07291895Not Applicable

High Dose Radiotherapy for Palliation (Hi-D)

Not Yet Recruiting
NCT06918951Not Applicable

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Recruiting
NCT06529081Not Applicable

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

Recruiting
NCT07116577Phase 2

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Not Yet Recruiting
NCT02223923Phase 1

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours

Unknown
NCT06398314Not Applicable

Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors

Recruiting
NCT05947513Not Applicable

Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial

Recruiting
NCT06524804Phase 1

A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors

Terminated
NCT02392871Phase 1

Radiotherapy & Combi in Metastatic Melanoma

Completed
NCT05002140Phase 1

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

Completed
NCT01446744Phase 2

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)

Active Not Recruiting
NCT03051672Phase 2

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

Terminated
NCT03927495Phase 2

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Unknown
NCT03797755

Prognosis of Patient Evaluated for Palliative Radiotherapy

Unknown
NCT03658434Not Applicable

Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer

Unknown
NCT01341756Phase 2

Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial

Unknown

All 20 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
20